Customized Organs from SpaceHow weightlessness could change human lives
22.11.2025 - von Maria Birlem
Reading Time: 11 Minutes
|
Due to its weightlessness, space offers enormous opportunities for production. The unique conditions of microgravity, for example, can simplify the development of organs and tissues from the body’s own stem cells, allowing therapies to be developed in a more targeted manner. Even though many independent initiatives are currently emerging to explore this and other potential applications, their success is not a foregone conclusion. The success of a thriving space economy, especially in Europe, also requires smart policies that understand how to develop the right framework conditions.
Severe congenital heart defects, such as those that can occur in premature babies, often lead to long-term and complex treatments. These include repeated operations, long-term medication, limited physical abilities, and an overall significantly reduced quality of life. In many cases, the only option is an organ transplant.
In Germany and Europe, thousands of patients are waiting for a donor organ, while the number of available organs has for years fallen significantly short of actual medical demand. Cardiological and other diseases further complicate the situation, as considerable challenges remain even after a successful transplant,. The immune system recognizes the transplanted organ as foreign, which can lead to rejection.. To prevent this, those affected must take immunosuppressive drugs for the rest of their lives, which protect the organ but are sometimes associated with significant side effects. In addition, the functional life of donor organs is limited. A transplanted heart typically lasts about ten to 15 years or slightly longer in the best case.
A concrete example illustrates this problem: A boy with a complex congenital heart defect requires several cardiac surgeries in early childhood. In adolescence, his condition deteriorates to such an extent that he must be permanently monitored in the hospital and connected to medical support systems. Only after a long wait does he receive a suitable donor heart. The transplant is successful, but the long-term limitations remain—lifelong immunosuppression and a limited organ lifespan. This example is not an exception, but rather a structural problem in transplant medicine.
Patient-specific organs from stem cells as a vision
A central research approach in modern regenerative medicine is the use of the patient’s own stem cells to generate tissue or entire organs in future. The goal is to provide patient-specific, immunologically highly compatible organs in the long term, minimize rejection reactions, significantly reduce the need for immunosuppression, and make the availability of organs independent of the number of donors.
Various technologies are combined to achieve this objective. Induced pluripotent stem cells, i.e., reprogrammed body cells, serve as the starting material and can be differentiated into different tissue types. 3D bioprinting makes it possible to introduce cells into defined spatial structures and thus build complex tissue arrangements in a targeted manner. Organoids, i.e., miniaturized, organ-like tissue structures, form an important intermediate stage in this process.
Although they are not yet fully functional organs, they replicate essential characteristics of the corresponding organ and are already suitable for more precise drug testing and active ingredient screening—especially when they are generated specifically for a patient and thus represent the tissue of a specific individual. The great medical dream is to eventually use these technologies to develop fully functional, transplantable organs that are tailored precisely to the individual patient.
Gravity, vascularization, and the technical limitations of Earth
On Earth, the production of complex, functional tissue structures face two key physical and biological hurdles. On the one hand, gravity causes soft, freshly printed cell constructs to deform or collapse under their own weight. To prevent this, support structures known as scaffolds are used. These scaffolds must later be biodegraded or removed without damaging the tissue. This process is technically demanding and not always fully controllable, which can impair both the function and stability of the tissue.
On the other hand, vascularization, i.e., the formation of a finely networked vascular system, is one of the greatest challenges. A functional organ requires a dense network of blood vessels to supply oxygen and nutrients and remove metabolic waste products. The formation of stable, functional blood vessels in three-dimensional structures has so far only been achieved to a limited extent on Earth. Especially in thicker tissues without sufficient perfusion, oxygen deficiency, cell death, and loss of function can occur quickly. At present, these limitations slow down the development of fully functional, transplantable organs from bioprinters and make it clear that new environmental conditions and approaches are needed.
Why microgravity can have such a big impact
Microgravity in near-Earth orbit fundamentally changes the boundaries for biological processes. In this environment, gravity has virtually no effect, structures collapse significantly less, and cells can organize themselves more homogeneously in three dimensions. Transport processes such as diffusion and convection, as well as cell-cell interactions, proceed differently than on Earth and can promote certain biological developments. Experiments with tissue and organoids in microgravity have shown that three-dimensional structures can grow more stably and require less extensive support structures.
There is also evidence that microgravity improves the tendency to form small blood vessel networks and that organoids are more prone to vascularization than under conditions on the Earth’s surface. From a technical point of view, low Earth orbit is particularly interesting. It can be reached relatively quickly, requires less energy than higher orbits, and already has infrastructure in place, such as the International Space Station and, in future, new commercial space stations. This makes space a potentially ideal laboratory environment for complex bioengineering and opens up a new approach to overcoming the existing limits of tissue production on Earth.
From stem cells to tissue in orbit
To realize the production of individualized organoids and, in the long term, organs in space, an integrated system is required that encompasses all steps from cell procurement to the return of tissue to Earth. First, patient-specific stem cells are obtained on Earth and multiplied under controlled conditions. These cell populations are standardized, characterized, and quality assured to create a reproducible starting point for the subsequent steps. The cells, culture media, and reagents are then transported into orbit. Temperature and environmental conditions must be maintained in accordance with applicable quality and safety standards, which should be close to GMP requirements.
In orbit, biological laboratory units designed for operation in microgravity are then used in space stations or orbital platforms. A specialized 3D bioprinter adapted to this environment precisely deposits the cells and biomaterials to form organoids or more complex tissue structures. Automated media changes, integrated monitoring, and process control ensure a stable environment during the culture phase. In the subsequent maturation phase, the printed organoids or tissues are incubated in suitable bioreactors to promote the formation of functional structures, including vascularization.
Once culture and maturation are complete, the samples are loaded into return capsules, transported back to Earth, analyzed in specialized laboratories, and evaluated for functionality and quality. In the long term, suitable tissues could eventually be transferred to clinical applications.
The role of specialized actors: infrastructure and technology in LEO
This development requires specialized players who have mastered the technical and organizational aspects of research, development, and production in microgravity. Such companies or consortia typically offer flight-certified end-to-end services ranging from mission planning and execution to the logistics of transporting experiments and biological samples, integration into space systems, and returning the results to Earth. Access to laboratories in microgravity via existing platforms and future commercial LEO destinations enables experiments and production processes to be carried out in microgravity. At the same time, proprietary technologies for bioengineering in orbit such as complex 3D bioprinters are being developed, as well as automated culture systems designed for use in microgravity.
The aim of these activities is to systematically explore the potential of bioengineering in microgravity, address the needs of industries such as pharmaceuticals, medical technology, materials science, and the nutrition and health sector, and develop viable business models. This proactively secured access to commercial LEO platform providers allows such players to position themselves early in an emerging market segment that encompasses the commercial use of near-Earth orbit for research and production.
Commercial LEO Destinations
Commercial LEO Destinations is a NASA program to develop privately operated space stations in low Earth orbit to replace the ISS when it is decommissioned as scheduled. Instead of financing a new station itself, NASA is relying on commercial providers from whom it will purchase research and usage services in future. The program promotes innovation, reduces costs, and enables new applications in space—from science and industrial production to logistics and tourism. Several companies are currently developing modular, reusable stations designed to create a diverse and competitive infrastructure in low Earth orbit.
Fields of application beyond organ transplantation
The production of individualized organoids and, later, organs in space opens up a wide range of possible applications that go far beyond traditional transplant medicine. In transplant medicine, patient-specific, transplantable organs could be produced in the long term, significantly reducing the risk of rejection and decreasing dependence on donor organs. Waiting lists could be shortened or eventually become obsolete, while the quality of life of those affected would improve considerably.
In the field of individualized pharmacotherapy, patient-specific organoids enable the testing of active substances and therapeutic concepts directly on tissue that reflects the characteristics of the respective patient. On this basis, therapies could be selected and dosed more precisely, side effects could be reduced, and efficacy could be better predicted.
In toxicology and safety assessment, human organoids open up new possibilities for investigating the effects of substances in the cosmetic, chemical, or pharmaceutical sectors. Animal testing could be replaced or significantly reduced by human-relevant models, which would bring both ethical and scientific benefits. In addition, the use of microgravity offers considerable added value for basic research, for example, in the study of cell behavior, tissue organization, regeneration processes, and signaling pathways in an environment with altered physical conditions. The knowledge gained there can be incorporated into new approaches for tissue engineering and regenerative therapies on Earth.
Europe in the strategic competition for near-Earth orbit
Low Earth orbit is increasingly evolving from a predominantly state-dominated research space to a commercial economic space. In addition to the established spacefaring nations, the US is investing heavily in commercial space stations, cost-efficient launch systems, and new business models in the areas of in-orbit servicing and in-orbit production.
Although Europe has an excellent research landscape, a high level of space expertise, and numerous innovative companies, it has so far only built up a limited amount of its own independent infrastructure in low Earth orbit. Investment strategies are often cautious, regulatory frameworks are complex, and risk appetite is limited.
If Europe wants to be more than just a user of space biotech and production in space, but also a shaping player, targeted measures are needed. These include investments in European LEO infrastructure, the promotion of demonstration missions with clear commercialization prospects, and framework agreements that offer companies a reliable basis for planning. At the same time, a regulatory environment is needed that supports innovation, accelerates processes, and facilitates cooperation between space, medicine, biotechnology, and industry.
A future market with huge potential – not only for patients
The combination of stem cell technology, 3D bioprinting, and microgravity opens up new technological opportunities for transplant medicine and biomedicine as a whole. Individualized organs made from the patient’s own cells have the potential to significantly reduce dependence on donor organs, minimize rejection reactions, improve the quality of the patient’s life in the long term, and make therapies more precise and safer. At the same time, animal testing can be replaced or reduced in many areas by models relevant to humans.
The first building blocks on the way to achieving this have already been implemented: end-to-end services for research and production in microgravity, secure access to commercial LEO platforms, and the development of specialized 3D bioprinters for use in orbit.
The next steps include validating the technology in iterative missions, transferring the results to medical and industrial applications, and at the same time shaping the framework conditions in Europe to allow for the emergence of a viable market for space biotech and production in space. In the long term, this could lead to a situation in which a young person with a serious organ disease is no longer dependent on a donor organ from another person, but receives an organ created from their own cells – possibly produced in an orbital production facility in low Earth orbit.
Potentials: Innovation Resource Efficiency Services
You might also be interested in
